Physician profile
Jeffrey E Tomjack
NPI 1447225339
$3,269.48
in general payments reported to CMS, 2019-2025
28 companies · $591 in 2025
The $591 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $177 · 2021: $390 · 2022: $425 · 2023: $652 · 2024: $688 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.56 | 2019-2025 | Qulipta, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $624.20 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $209.55 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $201.99 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $168.94 | 2019-2025 | |
| Biogen, INC. | $160.12 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $120.26 | 2019-2023 | Injectafer |
| Meditrina | $119.17 | 2021 | |
| Organon LLC | $90.30 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $90.03 | 2022 | |
| Coopersurgical, INC. | $86.15 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $79.67 | 2021-2023 | |
| Conmed Corporation | $79.52 | 2024 | |
| Hologic Sales and Service, LLC | $73.27 | 2024-2025 | Acessa Provu System, Omni Hysteroscope, Myosure Tissue Removal Device |
| Merck Sharp & Dohme LLC | $70.68 | 2019-2023 | Gardasil 9 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $47.21 | 2022-2024 | Perclot |
| Exeltis, USA INC. | $43.11 | 2021-2025 | Slynd |
| Allergan, INC. | $38.44 | 2019-2020 | |
| Coloplast Corp | $35.18 | 2019 | |
| Therapeuticsmd, INC. | $33.79 | 2019-2021 | |
| Boston Scientific Corporation | $31.71 | 2019-2024 | Advantage System |
| Ethicon US, LLC | $29.26 | 2021 | |
| Avion Pharmaceuticals | $14.55 | 2022 | |
| Olympus America INC. | $14.22 | 2021 | |
| Covidien Lp | $13.81 | 2019 | |
| Exact Sciences Corporation | $13.11 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $13.02 | 2022 | |
| Agile Therapeutics, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tomjack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.